Department of Pathology, NHC Key Laboratory of Prevention and Treatment of Central Asia High Incidence Diseases, First Affiliated Hospital, Shihezi University School of Medicine, North 2 Road, Shihezi, Xinjiang, 832002, China.
Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine, North 2 Road, Shihezi, Xinjiang, China.
World J Surg Oncol. 2022 May 12;20(1):155. doi: 10.1186/s12957-022-02612-3.
C20orf54 has been identified as an esophageal squamous cell carcinoma (ESCC) susceptibility gene in previous genome-wide association studies. Here, we attempted to clarify the expression level of C20orf54 in ESCC, non-tumoral esophageal tissues, and esophageal squamous intraepithelial neoplasia (ESIN).
We assessed C20orf54 expression in 146 ESCC, 108 non-tumoral esophageal tissues, and 148 ESIN using immunohistochemistry on tissue microarrays. We also evaluated the possible correlations of C20orf54 expression with clinicopathological characteristics. The survival rates were analyzed using the Kaplan-Meier method and log-rank test.
C20orf54 expression was significantly lower in ESCC, high-grade ESIN, and low-grade ESIN than in the non-tumoral esophageal tissues. The level observed for ESCC was also significantly lower than that in low-grade ESIN and high-grade ESIN, whereas no difference was observed between high-grade ESIN and low-grade ESIN. Furthermore, the C20orf54 defective expression correlated significantly with differentiation, lymph node metastasis, and invasion depth. The overall survival time was inversely associated with lymph node metastasis, an advanced TNM stage (III + IV), and deeper invasion.
This study provides the first evidence of C20orf54 defective expression in ESCC and precancerous lesions, demonstrating a potential role in tumor progression and metastasis. C20orf54 could be used as a potential biomarker for the early detection of ESCC.
C20orf54 在前基因组关联研究中被鉴定为食管鳞状细胞癌（ESCC）易感性基因。在此，我们试图阐明 C20orf54 在 ESCC、非肿瘤性食管组织和食管鳞状上皮内瘤变（ESIN）中的表达水平。
我们使用组织微阵列免疫组织化学方法评估了 146 例 ESCC、108 例非肿瘤性食管组织和 148 例 ESIN 中的 C20orf54 表达。我们还评估了 C20orf54 表达与临床病理特征的可能相关性。使用 Kaplan-Meier 方法和对数秩检验分析生存率。
C20orf54 在 ESCC、高级 ESIN 和低级 ESIN 中的表达明显低于非肿瘤性食管组织。ESCC 的水平也明显低于低级别 ESIN 和高级 ESIN，而高级 ESIN 和低级别 ESIN 之间没有差异。此外，C20orf54 表达缺陷与分化、淋巴结转移和浸润深度显著相关。总生存时间与淋巴结转移、晚期 TNM 分期（III+IV）和更深的浸润呈负相关。
本研究首次提供了 C20orf54 在 ESCC 和癌前病变中表达缺陷的证据，表明其在肿瘤进展和转移中具有潜在作用。C20orf54 可作为 ESCC 早期检测的潜在生物标志物。
